(EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers. Moreover, we find a wide range of DLL3 expression in high-grade EP-NEN. We describe heterogenous DLL3 expression not only in SCLC but also in different ...
although 5 dose-limiting toxicities (DLTs) occurred––all reversible––including grade 3/4 cytokine release syndrome (CRS, n = 2), grade 3 confusional state (n = 1), grade 2 infusion-related reaction (n = 1), and grade 3 nervous system disorder (n = 1). ...
As of April 21, 2023, the median DOR had not yet been reached and responses appeared to be durable. In a total of 107 patients, 5 dose-limiting toxicities (DLTs) occurred; 2 patients experienced grade 3 or 4 cytokine release syndrome, 1 had grade 3 confusion state, 1 had grade...